There’s a growing unease in the gene therapy world that nobody wants to say out loud: permanent DNA edits are powerful, but they’re also permanent. If something goes wrong — off-target cuts, unintended integrations, immune reactions — you can’t take it back. The body doesn’t have an undo button for its own genome.
Tacit Therapeutics just emerged from stealth with $19 million in seed financing and a provocative counter-thesis: what if you could fix the mutation without ever touching the DNA?
Their platform works at the RNA level — specifically, RNA splicing. Instead of cutting and editing the genome like CRISPR does, Tacit’s approach redirects the cell’s own splicing machinery to repair disease-causing mutations as the RNA is being processed. The DNA stays intact. The correction happens downstream. And because you’re working with the cell’s native biology rather than introducing foreign editing components, the approach is potentially non-immunogenic — a word that makes every gene therapy investor sit up a little straighter.
The initial targets are Huntington’s disease and Dravet syndrome, two devastating neurological conditions where the current standard of care ranges from “inadequate” to “nonexistent.” Huntington’s in particular has been a graveyard for drug developers — antisense oligonucleotides failed, gene silencing approaches have struggled with delivery and durability. Tacit is betting that splicing offers a different path entirely.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The $19M seed is co-led by Civilization Ventures and KdT Ventures — two firms that have been quietly building conviction in RNA biology as a therapeutic frontier. At $19M, this is one of the larger seed rounds in the RNA medicine space recently, which tells you the pitch landed. The company’s platform integrates RNA biology, synthetic biology, and gene therapy engineering, suggesting this isn’t a one-trick tool but a modular system designed to go after multiple indications.
Here’s the bigger picture: we’re watching the RNA medicine space stratify in real time. First there was RNAi — Alnylam proved you could silence genes with small RNAs. Then came mRNA — Moderna and BioNTech proved you could instruct cells to make proteins. Then base editing emerged as a precision tool between CRISPR’s blunt cuts and traditional gene therapy. Now Tacit is planting a flag in the next layer: splicing.
Each wave has been more precise, more reversible, more aligned with the cell’s native machinery. Splicing-based therapies represent the logical next step — intervening at the point where RNA is being processed, using the cell’s own equipment, without permanent genomic alterations. It’s elegant biology. Whether it’s practical medicine is the $19 million question.
For early-stage investors tracking the evolution of genetic medicine, Tacit represents a thesis worth understanding now — before the modality has a name everyone recognizes. The companies that defined RNAi, mRNA, and base editing were all $19M seeds once, too.
